Sharekhan's research report on PI Industries
Robust Q3FY23 performance with a 24% y-o-y growth in CSM revenues and a 143 bps beat in OPM at 25.7% (up 387 bps y-o-y). PAT of Rs. 352 crore (up 58% y-o-y) was 17% above our estimates, reflecting strong margins, higher other income and lower tax. CSM revenues grew by 24% y-o-y to Rs. 1,329 crore was led by a 9% volume growth and 14% from favourable product mix, price & currency impact. Domestic revenue growth muted at 1.6% y-o-y due to high channel inventory. Margins remained strong led by better product mix, benefit of operating leverage and strict control over fixed overheads. The management maintained CSM revenue growth guidance of over 20% for the coming years, which we believe is conservative. PI expects new product launches to drive double-digit growth for domestic business and guided that current margin is sustainable. It invested Rs. 68 crore in PI Health Sciences and CSM order book remains strong at $1.8 billion. The recent 16% fall in stock price from 52-week high level is an investment opportunity given consistent earnings outperformance.
Outlook
We maintain a Buy rating on PI Industries with an unchanged PT of Rs. 4,200. A potential acquisition in the pharmaceutical space would improve long-term earnings growth outlook and makes us constructive on the stock. Stock trades at 27.7x its FY2025E EPS.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.